Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The Bill & Melinda Gates Medical Research Institute said it will use Matrix-M, the vaccine adjuvant used in Novavax's Covid shot, to advance its “early-stage vaccine programs.”

Novavax Partners With Gates Foundation Offshoot In Efforts To Develop Malaria And TB Shots

GAITHERSBURG, Md. , June 1, 2023  /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.

Novavax to Participate in the Jefferies Global Healthcare Conference

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

GAITHERSBURG, Md. , May 26, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU) following a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

Ocugen, Inc.

Novavax and Ocugen fell behind in the coronavirus vaccine race and their shares have plummeted. Now, both companies have revised their strategies.

Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?

Novavax, Inc. continues to rally on positive Covid news, but the vaccine demand continues to trend lower. The biotech now plans to slash operating expenses by up to 50% from 2022 levels in a further sign vaccine sales are cratering.

Novavax: Sell The Covid Rips

Cabaletta Bio

Community Health Systems

Exact Sciences

Moderna

Organogenesis Holdings

Pfizer

Ultragenyx Pharmaceutical

Viking Therapeutics

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

TipRanks reveals the top 10 health care sector analysts of the past decade

EVgo

Wayfair

One of the places to find the best stocks to short are by viewing the Short Interest tables of major financial publications like MarketWatch and the Wall Street Journal. It's there you find the heavily shorted stocks in the markets.

The 3 Best Stocks to Short in May 2023

The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Novavax (NASDAQ: NVAX ) stock will gain 7% by June 15. An-E (pronounced Annie) has made this kind of prediction before.

Artificial Intelligence Engine Predicts NVAX Stock to Gain 7% by June 15

Novavax's revenue nosedived in Q1, but it still expects up to $1.6 billion in sales this year. Cash burn continues to be a problem, however.

Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First

Novavax (NASDAQ: NVAX) stock price has dropped in the past five straight days as concerns about the company's outlook darkened. The shares were trading at $7.65, which was about 32% below this month's high of $11.31.

Novavax stock price volatility crashes amid existential risks

Canopy Growth

Plug Power

Sizable declines in the stock market can present ideal opportunities for investors to pounce. Wall Street analysts believe these downtrodden companies can soar in the quarters and years to come.

Wall Street Expects These Unique Stocks to Skyrocket 314% to 943%

Novavax has a game plan to try to avoid going out of business. That plan is going to involve chopping a lot of costs.

Up 40% in 1 Day, Is Novavax Stock a Buy Now?

Vaccine developer Novavax Inc. NASDAQ: NVAX stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza, respiratory syncytial and Ebola.

Is Novavax Finally Turning Things Around?

Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2023 Health Care Conference May 11, 2023 1:00 PM ET Company Participants John Jacobs - President & Chief Executive Officer Filip Dubovsky - President-Research and Development Conference Call Participants Alec Stranahan - Vice President & Senior Biotech Analyst Alec Stranahan Hey, everyone. Good afternoon and welcome to -- or I guess good morning.

Novavax, Inc. (NVAX) Presents at BofA Securities 2023 Health Care Conference

Novavax's John C. Jacobs detailed his plan to cut costs and manage cash flow.

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

GAITHERSBURG, Md. , May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

Carvana

Fueling the flames of speculative fervor, business news agency CNBC released its list of the most heavily shorted public securities. Topping the list stood used-car retailer Carvana (NYSE: CVNA ).

Short-Squeeze Stocks Alert: CVNA, NVAX Make Most-Shorted Stocks List

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

Novavax is cutting costs and restructuring to stay afloat as vaccine demand declines. As part of that effort, the company plans on cutting 25% of its workforce.

Is the Worst Over for Novavax?

Intel

The layoffs are all at least in the hundreds, and cite difficult economic times as the reason.

Layoffs Misery Continues In Tech With LinkedIn, Intel And Novavax All Axing Roles

Paramount Global

More than 136,000 employees were laid off by major U.S. companies in the first quarter of 2023.

Spring 2023 Layoff Tracker: Paramount, Novavax, LinkedIn Cut Hundreds Of Employees

Novavax, Inc. (NASDAQ:NVAX ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director of IR John Jacob - President & Chief Executive Officer Filip Dubovsky - Chief Medical Officer John Trizzino - Chief Commercial Officer & Chief Business Officer James Kelly - Chief Financial Officer & Treasurer Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Operator Good morning, and welcome to Novavax First Quarter 2023 Financial Results and Operational Highlights Conference Call.

Novavax, Inc. (NVAX) Q1 2023 Earnings Call Transcript

Novavax Inc shares surged Tuesday after the COVID-19 vaccine producer announced plans to cut expenses that include a roughly 25% workforce reduction.  The company said it plans to slash next year's research and development costs, along with selling, general and administrative expenses, by 40% to 50%.

Novavax to cut 25% of its workforce as Covid-19 vaccine sales fall off; shares pop

The shares of Novavax Inc (NYSE:NVAX) are soaring today, up 47.9% at $11.02 at last glance, after a series of updates.

News for Novavax Stock (NVAX)